Myeloma Minute: COVID-19 and Its Impact on People Living with Myeloma


| INNOVATION | Latest Research


COVID-19’s Impact on People Living with Myeloma: March 26, 2020 Update

At a time when the pandemic is spreading around the world, the IMF is especially grateful to be able to tap into our global network of colleagues for first-hand reports on the myeloma community. The good news: myeloma patients appear to be doing well. And Iceland is tackling COVID-19 research in its usual out-of-the-box way, with some intriguing results.


| ACTION | Advocacy Alert


Keep Up With the Federal Government’s Response to COVID-19

The IMF Advocacy Team is working to keep you up to date on the Federal Government’s response to COVID-19. Follow the webpage at the link below to learn the latest as to what the government has done to address the virus. The IMF Advocacy Team is happy to answer any questions you may have. You can reach them anytime at [email protected].


| EDUCATION | Workshop


| INSPIRATION | Virtual Race


IMF Regional Community Workshops Are Postponed
Cabin Fever: Schedule Your Own Private Run/Walk for This Year’s Miles for Myeloma

Due to the increasing number of COVID-19 cases in the U.S. and the potential impact on the health and safety of myeloma patients, the IMF is postponing all in-person patient education meetings. The Regional Community Workshops in Birmingham, Alabama; Kansas City, Kansas; Edina, Minnesota; and Detroit, Michigan have been postponed until further notice. Follow the IMF Events page for updates.

With a focus on the health and well-being of our participants and the growing concerns over the COVID-19 (coronavirus) outbreak, we are canceling the in-person event. The Miles for Myeloma 5K Run/Walk is NOW VIRTUAL! The safety of our myeloma patients along with their friends and family is our priority. Visit the link below to learn about this new and exciting style of racing.



| INNOVATION | Latest Research


Results from a Melflufen Study Published in the Lancet Haematology

Results from the Oncopeptides’ O-12 M1 study was published in The Lancet Haematology. The study used melflufen plus dexamethasone in heavily pre-treated relapsed/refractory multiple myeloma patients. The patients had an “overall response rate (ORR) of 31%, a median duration of response (DOR) of 8.4 months, and a median overall survival (OS) of 20.7 months.”


| INSPIRATION | Patient Story


Climbing the Mountain

Meet Tim. He is a husband, father of twin boys, a hiker, a kayaker, and a mountain-climber. Tim is also a multiple myeloma patient. He says, “When you get knocked down, you get back up, always, no matter what. Resilience means looking at that enormous mountain and knowing that I can get to the top by taking it one step at a time, never giving up!” Earlier this year, Tim accomplished his lifelong goal of climbing Mt. Kilimanjaro. During this challenging time, people like Tim provide us with hope and inspiration. Read a transcript of a speech that he gave at the Brian D. Novis Research Grant reception at the 2019 American Society of Hematology annual meeting.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

April 25, 2020
VIRTUAL Miles for Myeloma 5K Run/Walk
Philadelphia, PA

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.